Alteplase is currently the only approved thrombolytic agent for treatment of acute ischaemic
stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic …

Background Whether thrombectomy alone is equally as effective as intravenous alteplase
plus thrombectomy remains controversial. We aimed to determine whether thrombectomy …

Importance Patients with atrial fibrillation (AF) treated with mechanical thrombectomy (MT)
for acute ischemic stroke (AIS) have been reported to experience worse outcomes …

卒中是致残和致死的主要疾病之一, 急性缺血性卒中约占全部卒中的80%.
急性缺血性卒中治疗的关键在于尽早开通阻塞血管, 挽救缺血半暗带. 目前被证实有效的急性缺 …

Background Current evidence supports the use of intravenous thrombolysis with alteplase in
patients with wake-up stroke selected with MRI or perfusion imaging and is recommended in …

Background Intravenous thrombolysis is recommended before endovascular treatment, but
its value has been questioned in patients who are admitted directly to centres capable of …

Importance Clinical evidence of the potential treatment benefit of intravenous thrombolysis
preceding unsuccessful mechanical thrombectomy (MT) is scarce. Objective To determine …

Background Whether intravenous thrombolysis (IVT) prior to endovascular thrombectomy
(EVT) provides additional benefits in patients with acute ischemic stroke (AIS) and a large …

The last decade's progress in demonstrating the clinical benefit of endovascular
thrombectomy (EVT) in patients with large vessel occlusion stroke has transformed the …

Background: Existing data and clinical trials could not determine whether faster intravenous
thrombolytic therapy (IVT) translates into better long-term functional outcomes after acute …